Setmelanotide
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
Rhythm · Phase 2 · Completed · Enrollment 164
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Stage 1: Setmelanotide (Open-Label) | Obesity or overweight | n/r | 16 | n/r | -3.94% at week 16 |
| Stage 2: Setmelanotide (Double-Blind) | Obesity or overweight | n/r | 16 | n/r | n/r |
| Stage 2: Placebo (Double-Blind) | Obesity or overweight | n/r | 16 | n/r | n/r |